SCNLF (Scancell Holdings) FCF Yield %: -5.16 (As of Jun. 27, 2026)


SCNLF Scancell Holdings PLC SCNLF
20 GF Score
Price $0.28
! 2 Warning Signs
View Full Analysis

What is Scancell Holdings FCF Yield %?

Scancell Holdings SCNLF 20 FCF Yield % is -5.16 as of Jun. 27, 2026. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 1,418 Biotechnology companies, Scancell Holdings ranks better than 62.76% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Scancell Holdings's Trailing 12-Month Free Cash Flow is $-13.41 Mil, and Market Cap is $251.81 Mil. Therefore, Scancell Holdings's FCF Yield % for today is -5.16%.

The historical rank and industry rank for Scancell Holdings's FCF Yield % or its related term are showing as below:

SCNLF' s FCF Yield % Range Over the Past 10 Years
Min: -12.94   Med: -8.3   Max: -3.42
Current: -5.16


During the past 13 years, the highest FCF Yield % of Scancell Holdings was -3.42%. The lowest was -12.94%. And the median was -8.30%.

SCNLF's FCF Yield % is ranked better than
62.76% of 1418 companies
in the Biotechnology industry
Industry Median: -9.715 vs SCNLF: -5.16

Scancell Holdings's FCF Margin % for the quarter that ended in Oct. 2025 was 0.00%.


Scancell Holdings FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Scancell Holdings FCF Yield % Related Terms


Scancell Holdings FCF Yield % Historical Data

* Premium members only.

The historical data trend for Scancell Holdings's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings FCF Yield % Chart

Scancell Holdings Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.40 -58.53 -5.76 -16.80 -5.93

Scancell Holdings Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.22 -19.12 -6.76 -4.14 -15.80

SCNLF vs VRTX, REGN, ALNY: FCF Yield % Comparison

For the Biotechnology subindustry, Scancell Holdings's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's FCF Yield % falls into.


SCNLF
20GF Score
Scancell Holdings PLC SCNLF
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Scancell Holdings's FCF Yield % for the fiscal year that ended in Apr. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-10.431 / 176.0454138
=-5.93%

Scancell Holdings's annualized FCF Yield % for the quarter that ended in Oct. 2025 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-9.764 * 2 / 123.5997171
=-15.80%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -5.16 mean?
Scancell Holdings (SCNLF) has a FCF Yield % of -5.16 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Scancell Holdings and its competitors. According to the industry distribution chart, Scancell Holdings ranks #528 out of 1418 companies in the Biotechnology industry, placing it in the top 37.2%.
Is Scancell Holdings' FCF Yield % too high?
Scancell Holdings' current FCF Yield % is -5.16. Based on the distribution chart, Scancell Holdings ranks #528 out of 1418 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #528 out of 1418 companies for FCF Yield %. This puts Scancell Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Scancell Holdings and its competitors. Scancell Holdings's current FCF Yield % is -5.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current FCF Yield % of -5.16. The current FCF Yield % is -5.16. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current FCF Yield % is -5.16 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Other Exchanges SCLP:UKSCP:Germany
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score

Get the complete analysis for SCNLF

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price